Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating in a research report issued on Friday.

A number of other equities analysts have also weighed in on SUPN. Stifel Nicolaus lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating and set a $47.00 target price on the stock. in a research note on Tuesday, September 19th. They noted that the move was a valuation call. Piper Jaffray Companies reiterated a “hold” rating and set a $41.00 target price on shares of Supernus Pharmaceuticals in a research note on Tuesday, September 26th. FBR & Co started coverage on Supernus Pharmaceuticals in a research note on Thursday, October 19th. They set a “buy” rating and a $53.00 target price on the stock. Zacks Investment Research upgraded Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $47.00 target price on the stock in a research note on Wednesday, November 8th. Finally, BidaskClub upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 17th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $49.60.

Supernus Pharmaceuticals (NASDAQ SUPN) traded down $0.60 during trading hours on Friday, reaching $37.20. The company’s stock had a trading volume of 511,359 shares, compared to its average volume of 521,387. The company has a market capitalization of $1,937.71, a price-to-earnings ratio of 35.66, a price-to-earnings-growth ratio of 1.60 and a beta of 1.20. Supernus Pharmaceuticals has a 12-month low of $20.70 and a 12-month high of $50.04.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.02. The firm had revenue of $80.40 million for the quarter, compared to analyst estimates of $78.74 million. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. The business’s quarterly revenue was up 41.5% compared to the same quarter last year. equities analysts anticipate that Supernus Pharmaceuticals will post 1.07 earnings per share for the current year.

In related news, CFO Gregory S. Patrick sold 50,000 shares of the stock in a transaction that occurred on Friday, September 8th. The stock was sold at an average price of $47.60, for a total transaction of $2,380,000.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Padmanabh P. Bhatt sold 5,000 shares of the stock in a transaction that occurred on Friday, September 8th. The stock was sold at an average price of $49.86, for a total value of $249,300.00. Following the sale, the senior vice president now directly owns 12,500 shares in the company, valued at approximately $623,250. The disclosure for this sale can be found here. Insiders have sold 150,000 shares of company stock worth $7,055,350 in the last three months. 6.70% of the stock is currently owned by company insiders.

A number of large investors have recently modified their holdings of the stock. Pinebridge Investments L.P. grew its position in Supernus Pharmaceuticals by 1.3% during the second quarter. Pinebridge Investments L.P. now owns 6,624 shares of the specialty pharmaceutical company’s stock worth $285,000 after buying an additional 86 shares in the last quarter. Arizona State Retirement System grew its position in Supernus Pharmaceuticals by 0.4% during the second quarter. Arizona State Retirement System now owns 26,201 shares of the specialty pharmaceutical company’s stock worth $1,129,000 after buying an additional 100 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in Supernus Pharmaceuticals by 0.4% during the second quarter. The Manufacturers Life Insurance Company now owns 36,650 shares of the specialty pharmaceutical company’s stock worth $1,579,000 after buying an additional 128 shares in the last quarter. CS Mckee LP grew its position in Supernus Pharmaceuticals by 0.5% during the second quarter. CS Mckee LP now owns 42,050 shares of the specialty pharmaceutical company’s stock worth $1,812,000 after buying an additional 200 shares in the last quarter. Finally, Rhumbline Advisers grew its position in Supernus Pharmaceuticals by 0.3% during the second quarter. Rhumbline Advisers now owns 93,907 shares of the specialty pharmaceutical company’s stock worth $4,047,000 after buying an additional 288 shares in the last quarter. 98.47% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Supernus Pharmaceuticals (SUPN) Downgraded to “Hold” at ValuEngine” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/02/supernus-pharmaceuticals-supn-downgraded-to-hold-at-valuengine.html.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.